Graham Parry
Stock Analyst at Citi
(2.02)
# 3,328
Out of 4,712 analysts
231
Total ratings
60.2%
Success rate
0.4%
Average return
Main Sectors:
Stocks Rated by Graham Parry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Reiterated: Buy | CHF 135.00 | CHF 111.66 | +20.90% | 54 | Sep 9, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 17,800p | 11,650p | +52.79% | 14 | Sep 7, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 2,100p | 1,804p | +16.44% | 53 | Jul 29, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Buy | n/a | $347.70 | - | 5 | Mar 10, 2026 | |
| EPA: SAN Sanofi | Reiterated: Hold | €85.00 → €80.00 | €74.24 | +7.76% | 40 | Feb 20, 2026 | |
| SNY Sanofi | Reiterated: Buy | n/a | $42.85 | n/a | 17 | Jan 31, 2025 | |
| GSK GSK plc | Reiterated: Sell | $19 | $48.63 | n/a | 23 | Dec 6, 2024 | |
| NVS Novartis AG | Rated: Hold | $118 → $130 | $137.48 | n/a | 17 | Sep 11, 2024 | |
| BME: GRF Grifols, S.A. | Initiated Coverage: Buy | €20.00 | €9.96 | n/a | 1 | Sep 12, 2023 | |
| LON: HLN Haleon plc | Reiterated: Buy | 358p → 611p | 335p | n/a | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $88 | $145.65 | n/a | 1 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $50 | $27.78 | n/a | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $33.04 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 | $53.38 | n/a | 1 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $5.66 | n/a | 1 | Oct 26, 2017 |
Novartis AG
Sep 9, 2026
Reiterated: Buy
Price Target: CHF 135.00
Current: CHF 111.66
Upside: +20.90%
AstraZeneca PLC
Sep 7, 2026
Reiterated: Buy
Price Target: 17,800p
Current: 11,650p
Upside: +52.79%
GSK plc
Jul 29, 2026
Reiterated: Hold
Price Target: 2,100p
Current: 1,804p
Upside: +16.44%
Roche Holding AG
Mar 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $347.70
Upside: -
Sanofi
Feb 20, 2026
Reiterated: Hold
Price Target: €85.00 → €80.00
Current: €74.24
Upside: +7.76%
Sanofi
Jan 31, 2025
Reiterated: Buy
Price Target: n/a
Current: $42.85
Upside: n/a
GSK plc
Dec 6, 2024
Reiterated: Sell
Price Target: $19
Current: $48.63
Upside: n/a
Novartis AG
Sep 11, 2024
Rated: Hold
Price Target: $118 → $130
Current: $137.48
Upside: n/a
Grifols, S.A.
Sep 12, 2023
Initiated Coverage: Buy
Price Target: €20.00
Current: €9.96
Upside: n/a
Haleon plc
Mar 7, 2023
Reiterated: Buy
Price Target: 358p → 611p
Current: 335p
Upside: n/a
Mar 3, 2023
Reiterated: Hold
Price Target: $88
Current: $145.65
Upside: n/a
Feb 28, 2023
Reiterated: Hold
Price Target: $50
Current: $27.78
Upside: n/a
Sep 10, 2018
Downgraded: Sell
Price Target: n/a
Current: $33.04
Upside: n/a
Sep 10, 2018
Downgraded: Hold
Price Target: $34
Current: $53.38
Upside: n/a
Oct 26, 2017
Downgraded: Sell
Price Target: n/a
Current: $5.66
Upside: n/a